Johnson & Johnson is placing new remission data for its esketamine nasal spray Spravato at the center of its push to expand use in treatment-resistant depression (TRD). A poster presentation details the drug's ability to achieve remission in patients who have failed prior therapies, building on its existing FDA approval since March 2019.
Spravato, the more potent S-enantiomer of ketamine, targets the NMDA receptor through a novel mechanism distinct from standard antidepressants. The remission data from the poster underscores the drug's efficacy in a patient population where traditional oral medications often fall short, though specific numeric remission rates from this analysis were not disclosed in the source material.
The drug has evolved from ketamine's origins as an anesthetic synthesized by Calvin Stevens at Parke-Davis over sixty years ago. Now a blockbuster, Spravato's commercial trajectory reflects its growing adoption in psychiatry, with Johnson & Johnson highlighting this data to differentiate it from newer competitors and generic ketamine compounding.
Investor focus remains on Spravato's annual worldwide sales, which have grown steadily since approval, though exact figures were not provided in the source. The TRD market represents a significant opportunity, with Spravato positioned as a branded, patented alternative to off-label ketamine infusions.
Some clinicians and payers remain cautious about Spravato's cost and the requirement for in-clinic administration under Risk Evaluation and Mitigation Strategy (REMS) protocols, which limits patient access compared to oral antidepressants.